Carisma Therapeutics (CARM)

Carisma Therapeutics (CARM) Financial Statements


Carisma Therapeutics Financial Overview

Carisma Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.471; its P/E ratio is -0.47; and it has a dividend yield of 443.52%. Carisma Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 83.54M$ 3.80M$ 3.60M$ 3.24M-
Gross Profit$ 83.54M$ 3.80M$ 3.60M$ 3.16M-
EBIT$ -21.47M$ -21.43M$ -19.75M$ -22.88M$ -9.43M
EBITDA$ -19.43M$ -19.35M-$ -19.56M$ -9.44M
Net Income Common Stockholders$ -20.97M$ -21.43M$ -19.88M$ -24.46M$ -28.02M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 77.61M$ 94.14M$ 117.08M$ 138.97M$ 187.92M
Total Assets$ 89.55M$ 106.78M$ 133.01M$ 156.13M$ 189.17M
Total Debt$ 3.12M$ 2.75M$ 5.23M$ 5.47M$ 0.00
Net Debt$ -74.48M$ -91.39M$ -111.85M$ -133.49M$ -187.92M
Total Liabilities$ 63.02M$ 60.49M$ 66.31M$ 70.06M$ 30.98M
Stockholders Equity$ 26.53M$ 46.30M$ 66.75M$ 86.07M$ 158.19M
Cash Flow-
Free Cash Flow$ -16.66M$ -21.19M-$ -25.67M$ 2.69M
Operating Cash Flow$ -16.10M$ -21.00M-$ -25.53M$ 2.69M
Investing Cash Flow$ 10.44M$ 29.81M-$ -3.60M$ 59.76M
Financing Cash Flow$ 101.00K$ -2.03M-$ 67.74M$ 1.00K
Currency in USD

Carisma Therapeutics Earnings and Revenue History

Carisma Therapeutics Debt to Assets

Carisma Therapeutics Cash Flow

Carisma Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis